Breakthroughs In Treating Killer Diseases Could Lengthen Life

According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer’s, neonatal conditions, and diabetes. Therefore, discovering viable treatments for these issues is a worthwhile endeavor that could reduce the economic burden and potentially lengthen life. Here we consider this regarding GlaxoSmithKline Plc (NYSE: GSK), AstraZeneca Plc (NASDAQ: AZN), Johnson & Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).

Sadly, the Global Burden of Disease Study, published in October 2020, suggests that the world might be approaching a turning point in life expectancy gains. The study reveals a rise in exposure to key risk factors, combined with rising deaths from cardiovascular disease in some countries. This highlights the urgent need for global progress on healthcare and remedies.

GlaxoSmithKline Plc and Johnson & Johnson are working on treatments for respiratory diseases, AstraZeneca Plc is making strides in oncology medications, while Eli Lilly is developing life-altering Alzheimer's, diabetes and cancer drugs. Each of these drugs could potentially lead to extended life expectancy.

However, the number one global cause of death is cardiovascular disease (CVD), an area where innovation is particularly welcome. Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is one company hoping to make significant strides in this space.

Heart failure has remained the leading cause of death globally for the last 20 years, further exacerbated by mounting diabetes, obesity, and high blood pressure cases. Over 550,000 new heart disease cases are diagnosed in the U.S. annually. This devastating condition destroys quality of life, often results in death, and causes a severe economic burden.

Cardiol Therapeutics is focused on researching and developing an anti-inflammatory and anti-fibrotic therapy to treat CVD. Its lead product candidate, CardiolRx™, is a pharmaceutically produced oral formulation being clinically developed for use in cardiovascular medicine.

The company currently has one multi-national clinical trial ongoing, with another expected to commence shortly. Furthermore, it has just announced its third FDA IND authorization in CVD for its flagship formulation CardiolRx™.

This new IND authorization is for investigating the potential use of CardiolRx™ in treating patients with recurrent pericarditis, a cardiovascular, inflammatory disease and the most common of pericardial diseases. The company will evaluate whether this intervention could be a therapeutic option for those who are intolerant to current medical treatment or who require long-term administration of corticosteroids to control their disease.

Pericarditis refers to inflammation of the pericardium – the membrane, or sac, surrounding the heart. Symptoms include debilitating chest pain, shortness of breath, and fatigue, which result in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.

Cardiol's multicenter Phase II open-label pilot study of CardiolRx™ for recurrent pericarditis will run parallel with the company's multi-national Phase II acute myocarditis trial, which is expected to commence imminently.

Cardiol believes there is a significant opportunity to develop its oral formulation of CardiolRx™ as an orphan drug designation for the treatment of acute myocarditis and recurrent pericarditis, potentially adding significantly more value to the company.

Cardiol is also advancing its subcutaneous formulation of CardiolRx™ as a potential anti-inflammatory and anti-fibrotic therapy for treating chronic heart failure, specifically diastolic heart failure. There are 64.3 million people with heart failure globally, and it remains a leading cause of death and hospitalization. Associated annual healthcare costs in the U.S. alone exceed $30bn.

If Cardiol achieves its long-term goal of developing a treatment for diastolic heart failure, the addressable market will be huge. This is a massive health problem in the western world with no current standard of care. Plus, it is a condition that continues to grow in the developed world due to an increase in diabetes, hypertension, and obesity.

Cardiol Therapeutics is well funded through to 2024 and has no debt. As of March 2022, it had $74.8m in the bank, and 11% of its shares were insider and employee owned. It also had 4% ownership by pharmaceutical partners and research collaborators.

GlaxoSmithKline Plc (NYSE: GSK) is a pharmaceutical company with a strong portfolio of innovative and established medicines with leading market positions in respiratory disease and HIV. It is also a world leader in vaccine production. In 2021, GSK respiratory sales were up 21% AER, on the growth of Trelegy, which treats COPD and asthma, and Nucala for severe asthma.

AstraZeneca Plc (NASDAQ: AZN) achieved global distinction for its COVID-19 vaccine, but the company also treats a diverse range of conditions. In Q1, its Oncology total revenue grew 25% Y/Y, despite COVID-19 continuing to impact cancer diagnosis and treatment. AstraZeneca presented new data across its diverse portfolio of cancer medicines at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in February 2022.

The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) achieved positive results from its Phase 2b CYPRESS study of its respiratory syncytial virus (RSV) adult vaccine candidate. Results show that the vaccine candidate effectively protected against three clinical definitions of lower respiratory tract disease caused by RSV. It demonstrated vaccine efficacy of 70% to 80% in adults aged 65 and older. RSV is a very contagious virus and debilitating disease for both the very young and old.

Eli Lilly (NYSE: LLY) has a growing portfolio of medicines, including treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain. The FDA recently approved Lilly's Mounjaro™ (tirzepatide) injection. This is the first and only GIP and GLP-1 receptor agonist for treating adults with type 2 diabetes.

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of One Hundred and Eighty Thousand Dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

Tickers

40.46 usd

Articles